Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chlorambucil plus subcutaneous rituximab followed by rituximab maintenance in MALT lymphoma
2012-004896-38Phase 2Active
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and chlorambucil in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: Complete remission rate at 6 months. Started Dec 2013; status: active.
02
Drugs
rituximabchlorambucil
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2012-004896-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004896-38.